# Ampersand Biomedicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ampersand-biomedicines

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.ampersand.bio
- Total disclosed funding: $115M
- Latest round: Series B (Mar 19, 2025)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2020 by Noubar Afeyan, Ampersand Biomedicines, Inc. operates as a biotechnology research company that develops DNA-based diagnostics technologies using nucleic acid testing methods and offers assays for several diseases. In March 2025, Ampersand Biomedicines, Inc. raised USD 65 million in series B funding from returning investor Flagship Pioneering and new investor Eli Lilly & Company, with participation from other unspecified investors. As of March 2023, Avak Kahvejian is the Chief Executive Officer (CEO) of the company. Ampersand Biomedicines, Inc. is an inventor of medicines and body therapeutics that work at the site of disease. The company combines a localizing element that allows for disease-specific precision with a sensor designed specifically for disease modification, allowing researchers to examine many different areas of diseases in almost every area of the body. Additionally, the firm develops a platform named as AND-Platform that enables a new way of designing medicines that address, navigate, and designs the characterization of human biology, spanning healthy and diseased states. The company will use the March 2025 funding to improve the targeting of biologic drugs in order to reduce on-target, off-tissue toxicity.

## Funding rounds

- Series B, Mar 19, 2025, $65M — Flagship Pioneering, Eli Lilly & Company
- Series A, Mar 7, 2023, $50M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- Eli Lilly & Company — Series B